AAM Urges Supreme Court To Uphold Inter Partes Review
Submits Amicus Brief In Arthrex Litigation Over Constitutionality Of Judges
The AAM has insisted that the US Supreme Court should uphold the inter partes review framework, in an amicus brief filed as part of litigation that potentially threatens hundreds of IPR decisions.
You may also be interested in...
Laying out the 2021 outlook for US generics and biosimilars, AAM president and CEO Dan Leonard has urged US president-elect Joe Biden and lawmakers in the US Congress to act to maximize savings and access to medicines.
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.
Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.